Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 102.85%.

  • Lineage Cell Therapeutics' EBITDA Margin fell 12400.0% to 102.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 325.27%, marking a year-over-year decrease of 645700.0%. This contributed to the annual value of 226.11% for FY2024, which is 503900.0% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' EBITDA Margin stood at 102.85%, which was down 12400.0% from 715.37% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' EBITDA Margin peaked at 56.48% during Q4 2021, and registered a low of 1803.07% during Q1 2021.
  • For the 5-year period, Lineage Cell Therapeutics' EBITDA Margin averaged around 419.31%, with its median value being 301.45% (2021).
  • In the last 5 years, Lineage Cell Therapeutics' EBITDA Margin soared by 16809400bps in 2022 and then plummeted by -3629700bps in 2023.
  • Lineage Cell Therapeutics' EBITDA Margin (Quarter) stood at 56.48% in 2021, then plummeted by -514bps to 346.68% in 2022, then grew by 12bps to 304.69% in 2023, then soared by 42bps to 178.17% in 2024, then skyrocketed by 42bps to 102.85% in 2025.
  • Its EBITDA Margin was 102.85% in Q3 2025, compared to 715.37% in Q2 2025 and 433.09% in Q1 2025.